IL232743A0 - anticancer fusion protein - Google Patents

anticancer fusion protein

Info

Publication number
IL232743A0
IL232743A0 IL232743A IL23274314A IL232743A0 IL 232743 A0 IL232743 A0 IL 232743A0 IL 232743 A IL232743 A IL 232743A IL 23274314 A IL23274314 A IL 23274314A IL 232743 A0 IL232743 A0 IL 232743A0
Authority
IL
Israel
Prior art keywords
fusion protein
cancer fusion
cancer
protein
fusion
Prior art date
Application number
IL232743A
Other languages
English (en)
Hebrew (he)
Original Assignee
Adamed Sp Zoo
Pieczykolan Jerzy Szczepan
Pawlak Sebastian Dominik
Zerek Bartlomiej Maciej
Rozga Piotr Kamil
Szymanik Michal
Pieczykolan Anna Maria
Jaworski Albert Robert
Teska Kaminska Malgorzata Izabela
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamed Sp Zoo, Pieczykolan Jerzy Szczepan, Pawlak Sebastian Dominik, Zerek Bartlomiej Maciej, Rozga Piotr Kamil, Szymanik Michal, Pieczykolan Anna Maria, Jaworski Albert Robert, Teska Kaminska Malgorzata Izabela filed Critical Adamed Sp Zoo
Publication of IL232743A0 publication Critical patent/IL232743A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/55Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
IL232743A 2011-11-28 2014-05-21 anticancer fusion protein IL232743A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL397167A PL397167A1 (pl) 2011-11-28 2011-11-28 Przeciwnowotworowe bialko fuzyjne
PCT/IB2012/056806 WO2013080147A2 (en) 2011-11-28 2012-11-28 Anticancer fusion protein

Publications (1)

Publication Number Publication Date
IL232743A0 true IL232743A0 (en) 2014-07-31

Family

ID=47561689

Family Applications (1)

Application Number Title Priority Date Filing Date
IL232743A IL232743A0 (en) 2011-11-28 2014-05-21 anticancer fusion protein

Country Status (18)

Country Link
US (1) US20150044162A1 (en:Method)
EP (1) EP2785362A2 (en:Method)
JP (1) JP2015500228A (en:Method)
KR (1) KR20140097529A (en:Method)
CN (1) CN103974711A (en:Method)
AU (1) AU2012345494A1 (en:Method)
BR (1) BR112014012808A2 (en:Method)
CA (1) CA2856480A1 (en:Method)
EA (1) EA201491049A1 (en:Method)
HK (1) HK1201727A1 (en:Method)
IL (1) IL232743A0 (en:Method)
IN (1) IN2014CN04498A (en:Method)
MX (1) MX2014006369A (en:Method)
PH (1) PH12014501083A1 (en:Method)
PL (1) PL397167A1 (en:Method)
SG (1) SG11201402312WA (en:Method)
WO (1) WO2013080147A2 (en:Method)
ZA (1) ZA201404667B (en:Method)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
WO2014141094A1 (en) 2013-03-14 2014-09-18 Adamed Sp. Z O.O. Anticancer conjugate
IL294746B2 (en) 2014-01-27 2024-04-01 Molecular Templates Inc SHIGA toxin-free effector subunit-containing polypeptides for mammalian applications
US20170002046A1 (en) * 2014-03-11 2017-01-05 Molecular Templates, Inc. Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2919749T3 (es) * 2014-06-11 2022-07-28 Molecular Templates Inc Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
KR20170110601A (ko) 2015-02-05 2017-10-11 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 영역을 포함하는 다가 cd20 결합 분자 및 이들의 강화된 조성물
WO2016127346A1 (zh) * 2015-02-11 2016-08-18 四川大学华西医院 一种肿瘤坏死因子相关凋亡诱导配体变异体及其制备方法和用途
US20180258143A1 (en) * 2015-05-30 2018-09-13 Molecular Templates, Inc. De-Immunized, Shiga Toxin A Subunit Scaffolds and Cell-Targeting Molecules Comprising the Same
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
KR101732126B1 (ko) 2015-11-05 2017-05-02 한국생명공학연구원 췌장암 치료용 융합 단백질 및 이의 용도
PL233352B1 (pl) * 2016-09-15 2019-10-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe białko fuzyjne
EP3551645A1 (en) 2016-12-07 2019-10-16 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
CN106632680A (zh) * 2016-12-27 2017-05-10 上海交通大学 植物体系表达人源化抗agr2单克隆抗体18a4的质粒构建
CA3049456A1 (en) 2017-01-25 2018-08-02 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
US12186376B2 (en) * 2018-03-06 2025-01-07 The Johns Hopkins University Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
IL268443B2 (en) 2018-04-17 2024-07-01 Molecular Templates Inc HER2-targeted molecules containing Shiga toxin subunit A scaffolds, without vaccination
EP3984546A4 (en) * 2019-05-15 2023-09-27 Universidad de Granada GENE THERAPY WITH THE HOKD AND LDRB GENES FOR CANCER TREATMENTS
CN113354738B (zh) * 2020-03-05 2022-09-09 绍兴德方华生物技术有限公司 融合毒素VEGF165b/mGEL及其编码基因与应用
IL300701A (en) * 2020-08-17 2023-04-01 Atb Therapeutics Immunotoxin-containing immunotoxin-containing or renase
CN114681599B (zh) * 2020-12-31 2024-07-02 中国科学院上海药物研究所 一种阳离子脂质体疫苗及其制备方法和用途
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763223A (en) 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
WO2001060393A1 (en) 2000-02-16 2001-08-23 Bechtel Bwxt Idaho, Llc Selective destruction of cells infected with human immunodeficiency virus
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
CN1257187C (zh) * 2003-10-22 2006-05-24 上海恰尔生物技术有限公司 钙网蛋白-肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
NZ547274A (en) 2003-11-03 2009-02-28 Sunbio Biotech Pharmaceuticals A recombinant protein with cancer suppression action, its encoding gene and use
US7252993B2 (en) 2004-03-12 2007-08-07 Battelle Energy Alliance, Llc Plasmids encoding therapeutic agents
US8907060B2 (en) 2005-07-29 2014-12-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mutated Pseudomonas exotoxins with reduced antigenicity
PT1915626E (pt) 2005-08-16 2012-02-03 Genentech Inc Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos
US20100215670A1 (en) 2006-10-30 2010-08-26 Jeannick Cizeau Immunotoxin Fusions Comprising An Antibody Fragment and a Plant Toxin Linked by Protease Cleavable Linkers
EP2097529A4 (en) 2006-12-29 2010-03-24 Osprey Pharmaceuticals Usa Inc METHOD FOR SELECTION AND PRODUCTION OF MODIFIED TOXINS, MODIFIED TOXINE CONJUGATES AND USES THEREOF
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
GB0723059D0 (en) 2007-11-23 2008-01-02 Nat Univ Ireland Improved cytokine design
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
WO2009140469A2 (en) 2008-05-14 2009-11-19 Genentech, Inc. Methods of using apo2l/trail to treat cancer
CN102137869B (zh) * 2008-06-30 2018-07-06 宾夕法尼亚大学 Fn14/TRAIL融合蛋白

Also Published As

Publication number Publication date
AU2012345494A1 (en) 2014-07-10
CN103974711A (zh) 2014-08-06
EA201491049A1 (ru) 2014-10-30
PL397167A1 (pl) 2013-06-10
US20150044162A1 (en) 2015-02-12
PH12014501083A1 (en) 2014-08-04
ZA201404667B (en) 2015-09-30
HK1201727A1 (en) 2015-09-11
IN2014CN04498A (en:Method) 2015-09-11
BR112014012808A2 (pt) 2019-09-24
JP2015500228A (ja) 2015-01-05
CA2856480A1 (en) 2013-06-06
WO2013080147A2 (en) 2013-06-06
SG11201402312WA (en) 2014-06-27
MX2014006369A (es) 2014-07-09
KR20140097529A (ko) 2014-08-06
WO2013080147A3 (en) 2014-02-13
EP2785362A2 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
IL232743A0 (en) anticancer fusion protein
ZA201300677B (en) Anticancer fusion protein
LT2661496T (lt) Priešvėžinis sulietas baltymas
ZA201405460B (en) Anticancer fusion protein
ZA201303449B (en) Anticancer fusion protein
SG10201500208SA (en) Npp1 fusion proteins
GB201113811D0 (en) Protein recovery
EP2698386B8 (en) Fusion protein
ZA201308597B (en) Anticancer fusion protein
EP2657337A4 (en) FUSION PROTEIN
ZA201207425B (en) Fusion protein
GB201114701D0 (en) Fusion proteins
GB201107189D0 (en) Fusion proteins
GB201104152D0 (en) Fusion Polypeptide
HUP1100282A2 (en) Protein factor
AU2011905145A0 (en) Fusion Protein
GB201103169D0 (en) Protein expression
HK1189602A (en) Anticancer fusion protein
PL393146A1 (pl) Przeciwnowotworowe białko fuzyjne
GB201112985D0 (en) Polypeptide
GB201112849D0 (en) Polypeptide
PL120305U1 (pl) Przegub podlokietnika
GB201106130D0 (en) Polypeptide
AU2011901207A0 (en) Anti-cancer peptides
GB201007955D0 (en) Somatosatin fusion proteins